贝那普利联合黄葵胶囊对中小量蛋白尿IgA肾病患者尿MCP-1的影响

Effectiveness of benazepril combined with Huangkui capsule on urinary MCP-1 in patients with a small amount of proteinuria of IgA nephropathy

目的探讨贝那普利联合黄葵胶囊对中、小量蛋白尿IgA肾病患者尿单核细胞趋化因子-1（MCP-1）的影响。方法中、小量蛋白尿IgA肾病82例随机分为两组，观察组41例，对照组41例，观察组采用常规治疗加用贝那普利联合黄葵胶囊，对照组采用常规治疗加用贝那普利，两组共治疗8周。测定治疗前后尿MCP-1。结果观察组共有40例患者完成实验，总有效率为100％；对照组共有39例患者完成实验，总有效率为87．2％，两组比较差异有统计学意义（P〈0．05）。两组治疗后24h尿蛋白均有明显下降，并且与对照组治疗后比较，观察组下降更明显（P〈0．05）；两组血肌酐、尿素治疗前后没有明显变化（P〉0．05）。治疗后两组患者尿MCP-1均有明显降低，并且与对照组治疗后比较，观察组下降更明显（P〈0．05）。结论贝那普利联合黄葵胶囊可以明显降低中、小量蛋白尿IgA肾病患者尿MCP-1的表达。

Objective To study the effectiveness of benazepril combined with Huangkui capsule on urinary monocyte chemotactic factor-1 （ MCP-1 ） in patients with a small amount of proteinuria of IgA nephropathy. Methods Eighty-two patients with a small amount of proteinuria of IgA nephropathy were randomly divided into two groups, the observation group（41 cases） and the control group（41 cases）. The patients in the observation group were treated with benazepril combined with Huangkui capsule, while the patients in the control group were treated with benazepril. They were all treated for 8 weeks. Urinary MCP-1 were detected before and after treatment. Results For the observation group, a total of 40 pa-tients completed the experiment, and the total effective rate was 100%. For the control group, 39 patients completed the experiment, and the total effective rate was 87.2%, there was significant difference be- tween the two groups （P 〈 0. 05 ）. Twenty-four hours urine protein in the two groups after treatment were significantly decreased, and compared with the control group, the observation group decreased more sig- nificantly （P 〈 0. 05 ）. Two sets of serum creatinine, blood urea before and after treatment did not change significantly （P 〉 0. 05 ）. After treatment, urinary MCP-1 were significantly reduced, and com- pared with the control group, the observation group decreased more significantly （ P 〈 0.05 ）. Conclu-sions Benazepril combined with Huangkui capsule can significantly decrease urinary MCP-1 in patients with a small amount of proteinuria of IgA nephropathy.